High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Leukemia & lymphoma (Impact Factor: 2.89). 02/2012; 53(7):1306-10. DOI: 10.3109/10428194.2011.654339
Source: PubMed


Serum thymidine kinase 1 (TK1) is a sensitive marker of tumor cell proliferation. TK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma. In this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL). The TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, β(2)-microglobulin level, lactate dehydrogenase level and B symptoms. No correlation was found with FL grade or Ki-67 proliferation index. Cox regression analysis identified high TK1 levels (≥ 15I U/L) as a prognostic factor for overall survival (hazard ratio 2.91, p = 0.019) and progression-free survival (hazard ratio 1.94, p = 0.022) independent of FLIPI score variables. Thus, TK1 levels may help to refine risk assessment in the modern immunotherapy era.

Download full-text


Available from: Vit Prochazka,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor-related biomarkers are used for the diagnosis, prognosis and monitoring of treatments and follow-up of cancer patients, although only a few are fully accepted for the detection of invisible/visible tumors in health screening. Thymidine kinase 1 (TK1), a cell cycle-dependent and thus a proliferation-related marker, has been extensively studied during the last decades, using both biochemical and immunological techniques. Therefore, TK1 is an emerging potential proliferating biomarker in oncology that may be used for the prognosis and monitoring of tumor therapy, relapse and survival. In addition, TK1 concentration in serum (STK1p) is a useful biomarker in healthy screening for the detection of potential malignancy development as well as the identification of early-stage tumors, with a few false-positive cases (ROC value, 0.96; tumor proliferation sensitivity, 0.80; specificity, 0.99). In this review, we examine results regarding the expression of STK1p and TK1 in relation to cancer patients and STK1p in health screening published between 2000 and 2012. The use of tumor-related markers recommended by international cancer organizations is also discussed. This review provides valuable information for applications in tumor patients, in health screening and for cancer research.
    Molecular and Clinical Oncology 01/2013; 1(1):18-28. DOI:10.3892/mco.2012.19
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT The purpose of this study was to investigate prognostic factors for overall survival (OS) among previously untreated diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP. We evaluated four biological parameters including thymidine kinase activity (TK). This study looked at 183 patients. The median level of TK was 14.0 IU/L, which we chose as the cut-off. After a median follow-up time of 53.0 months, OS rate at 4 years in the high TK arm and low TK arm were 46.7% and 66.7% (p = .001). By multivariate analysis, OS was significantly worse in high-TK arm (hazard ratio 2.705; p = .045). Complete response (CR) rate among high TK arm was significantly worse than low TK arm. OS was significantly better in patients who had achieved CR than partial response or less. In conclusion, high TK activity was a strong predictor for short OS and poor response among patients with previously untreated DLBCL treated with R-CHOP.
    Leukemia & lymphoma 03/2013; 54(11). DOI:10.3109/10428194.2013.779690 · 2.89 Impact Factor
  • Source

    Leukemia & lymphoma 06/2013; 54(11). DOI:10.3109/10428194.2013.807513 · 2.89 Impact Factor
Show more